Merck Sharp & Dohme Llc

This early-stage study is testing the safety and immune response of an experimental HPV vaccine called V540D in 72 healthy adults. The vaccine is designed to protect against the same 9 HPV types as the current Gardasil 9 vaccine, plus additional cancer-causing types. Researchers …

This study is testing experimental combinations of immune and targeted drugs for people with advanced kidney cancer that has spread. The research aims to find safe and effective treatment options for 400 participants who haven't received prior treatment for their advanced cancer.…

This study is testing an experimental drug called zilovertamab vedotin for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma that has returned or hasn't responded to at least two prior treatments. The main goals are to see if the drug shrinks tum…

This large, late-stage study is testing whether a new oral drug called MK-0616 can help prevent serious heart and blood vessel problems in people at high risk. About 14,550 adults who are already taking cholesterol-lowering medication will receive either the new drug or a placebo…

This study is testing whether adding a personalized mRNA vaccine (V940) to a standard immunotherapy drug (pembrolizumab) is better at preventing melanoma from coming back after surgery than the drug alone. It involves about 1,089 people with high-risk melanoma who have had their …

This study tested whether a drug called pembrolizumab could prevent melanoma from coming back after surgery in high-risk patients. Over 1,000 participants who had their melanoma surgically removed were randomly assigned to receive either the drug or a placebo. The main goal was t…

This study is testing whether adding the drug palbociclib to belzutifan works better than belzutifan alone for advanced kidney cancer. It involves 60 patients whose cancer has worsened despite at least two prior treatments. The main goals are to find a safe dose for the combinati…

This large, late-stage study is testing whether adding two newer drugs (lenvatinib and pembrolizumab) to standard chemotherapy works better than chemotherapy alone for people with advanced stomach or esophageal cancer that has spread. The main goal is to see if the three-drug com…

This study is testing whether a new two-drug combination (MK-1308A) works better than other treatments for people with advanced colorectal cancer that has spread and has specific genetic features (MSI-H/dMMR). The trial involves 302 participants who either haven't received treatm…

This early-stage study is testing the safety of a new cancer drug called sacituzumab tirumotecan in Japanese patients. The drug is being given alone and in combination with an existing immunotherapy (pembrolizumab) to people with advanced solid tumors or a specific type of advanc…

This study is testing an investigational drug called tulisokibart for people with moderate to severe hidradenitis suppurativa (HS), a chronic, painful skin condition. The main goal is to see if the drug can reduce the number of painful abscesses and nodules by at least 50% after …

This study tested an immunotherapy drug called pembrolizumab in people with many different types of advanced solid tumors that had stopped responding to standard treatments. The main goal was to see if the drug could shrink tumors and to identify biological markers that might pre…

This study is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help children and young adults with newly diagnosed Hodgkin lymphoma who are not responding well enough to initial chemo alone. The trial will enroll about 340 participants to s…

This study is testing a new drug called zilovertamab vedotin (MK-2140) for people with several types of advanced B-cell blood cancers that have come back or stopped responding to other treatments. The main goals are to see if the drug is safe and if it can shrink or eliminate the…

This study is testing a new once-daily pill combination (doravirine/islatravir) for people who have HIV but have never taken medication for it. It will compare this new pill to a standard HIV treatment to see if it works just as well at keeping the virus under control and if it i…

This large, late-stage study is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without bevacizumab) works better than chemotherapy alone for women with recurrent ovarian cancer that has stopped responding to platinum-based drugs. The…

This study aimed to see if adding an experimental drug called boserolimab to standard pre-surgery treatment could better treat high-risk, early-stage triple-negative breast cancer. It planned to test the safety of this combination and measure how many patients had no detectable c…

This study is testing if people with HIV who are already successfully controlling their virus can safely switch to a new, simpler two-drug pill (doravirine/islatravir) taken once daily. It compares this new pill to people continuing their current HIV medications to see if it work…

This study is testing whether adding a personalized mRNA vaccine (V940) to a standard immunotherapy drug (pembrolizumab) is better at preventing kidney cancer from coming back after surgery than the immunotherapy drug alone. It involves about 272 people who have had surgery for i…

This large, late-stage study is testing an investigational drug called tulisokibart (MK-7240) for people with moderate to severe ulcerative colitis. It aims to see if the drug is better than a placebo at getting people into clinical remission, both in the short term (12 weeks) an…

This early-stage study is checking if a new HIV medication called ulonivirine (MK-8507) affects heart rhythm in healthy people. Researchers are measuring how the drug changes a specific heart rhythm interval and tracking how much of the drug stays in the body over time. The study…

This study is checking the long-term safety and effectiveness of a daily HIV pill (doravirine/islatravir) in people who are already taking it from earlier research. It follows 641 adults with HIV for 96 weeks to monitor side effects and see how well the virus remains controlled. …

This is the first human study of a new cancer drug called MK-6837. Researchers are testing it alone and combined with an existing immunotherapy (pembrolizumab) in 168 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find…

This study is testing an experimental drug called MK-2870 (sacituzumab tirumotecan) for people with advanced endometrial cancer that has returned or progressed after standard platinum-based chemotherapy and immunotherapy. It will compare MK-2870 to standard chemotherapy chosen by…

This large, late-stage trial is testing whether adding the immunotherapy drug pembrolizumab to the standard BCG treatment works better for controlling high-risk bladder cancer that hasn't spread into the muscle. It will compare the combination against BCG alone in nearly 1,400 pe…

This study is testing if adding two drugs, lenvatinib and pembrolizumab, to a standard liver cancer procedure (TACE) works better than the procedure alone. It involves about 480 adults with liver cancer that is confined to the liver but cannot be cured by surgery or transplant. T…

This study is testing a new, under-the-skin version of an immunotherapy drug (pembrolizumab) for adults whose Hodgkin lymphoma or a related B-cell lymphoma has come back or not responded to prior treatments. The main goals are to see how the drug behaves in the body when given th…

This study is testing new drug combinations for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It will enroll 48 participants whose cancer has progressed despite previous treatment. The trial aims to find new options to control the dise…

This study is testing if a new combination of two drugs (islatravir and ulonivirine), taken just once a week, can keep HIV under control as effectively as a standard daily pill regimen. It will involve about 150 adults whose HIV is already well-managed on daily medication. The ma…

This study is testing if adding an immunotherapy drug called pembrolizumab to standard chemotherapy works better than chemotherapy alone for a specific type of advanced breast cancer. It is for people whose cancer has spread or returned, is no longer responding to hormone therapy…

This large, late-stage trial is testing if adding a newer drug (sacituzumab govitecan) to a standard immunotherapy (pembrolizumab) works better than the immunotherapy alone for adults with a specific type of advanced lung cancer. The main goals are to see if the combination helps…

This study is testing an experimental drug called raludotatug deruxtecan for people with advanced cancers of the digestive system (like pancreatic, stomach, or colon cancer) that have spread or cannot be removed by surgery. The drug is designed to find cancer cells and deliver tr…

This study is testing whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent cancer from returning in people with high-risk muscle-invasive bladder cancer after surgery. The vaccine is custom-made for each person based on …

This study is testing whether a new combination of two drugs (belzutifan plus lenvatinib) works better than an existing drug (cabozantinib) for people with advanced kidney cancer that has continued to grow despite prior immunotherapy. The main goals are to see which treatment hel…

This study is testing whether an experimental drug called MK-5475 can help adults who have high blood pressure in their lungs (pulmonary hypertension) caused by chronic obstructive pulmonary disease (COPD). The main goal is to see if people taking the drug can walk farther in six…

This large, late-stage study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) works better for men whose prostate cancer has spread. It aimed to see if the combination helps patients live longer and delays the cancer's…

This study continues testing sotatercept, an investigational medicine for pulmonary arterial hypertension (PAH), to check its long-term safety when given in weight-based doses. It's open only to people who completed a previous trial of this drug and haven't started commercial tre…

This early-stage study is testing the safety and initial effects of a new drug, belzutifan, given alone and in combination with other cancer drugs (lenvatinib and pembrolizumab) for people in China with advanced kidney cancer. It will enroll 45 participants to see how their bodie…

This study is testing whether a new oral medication called nemtabrutinib works better than standard chemoimmunotherapy for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), which are types of blood cancer. The main goal is to…

This study is testing if people with HIV who have their virus well-controlled on a standard three-drug pill can safely switch to a new two-drug pill (Doravirine/Islatravir). It will compare the new pill to staying on the current treatment to see if it works just as well at keepin…

This study is testing if a new under-the-skin injection of a cancer drug works as well as the standard intravenous (IV) drip. It involves adults with advanced non-small cell lung cancer who are receiving their first treatment. The main goal is to see if the body processes the inj…

This study allows people with HIV-1 who benefited from the two-drug combination doravirine/islatravir in earlier trials to continue receiving it. The main goal is to monitor the long-term safety and side effects of this treatment. It is open to about 2000 participants who are alr…

This large, late-stage study is testing whether adding the drug lenvatinib to a standard immunotherapy and chemotherapy combination helps people with advanced esophageal cancer that has spread. The main goal is to see if this three-drug approach helps patients live longer compare…

This study is testing whether an investigational drug called efinopegdutide can help treat a serious form of fatty liver disease called MASH that has progressed to cause permanent scarring (cirrhosis). About 80 adults with this condition will receive either the drug or a placebo …

This study is testing a new, simpler way to give an existing lung cancer drug. It compares giving the drug as an under-the-skin injection versus the standard method of an IV infusion. The main goals are to see if the injection gets similar drug levels into the body and is as safe…

This study is testing if a new under-the-skin injection of the cancer drug pembrolizumab works as well and is as safe as the standard intravenous (IV) infusion. It is for Japanese adults with advanced non-small cell lung cancer who are receiving it along with chemotherapy as thei…

This is an early-stage study to check the safety and how the body processes a new drug called MK-5684 (opevesostat) in Japanese men with advanced prostate cancer. The cancer has spread and no longer responds to standard hormone therapy or chemotherapy. The main goal is to see wha…

This study aims to understand the long-term safety and effectiveness of the experimental drug MK-0616 for lowering high cholesterol. It involves 3,000 adults who have already completed a previous trial with the same drug. The main goal is to see if the drug continues to work well…

This large, late-stage study is testing whether adding two newer drugs—an immunotherapy (pembrolizumab) and a maintenance therapy (olaparib)—to standard chemotherapy can help women with advanced ovarian, fallopian tube, or peritoneal cancer live longer without their cancer gettin…

This study is testing whether a pill called olaparib can help control advanced cancers that have specific genetic changes and have stopped responding to standard treatments. It involves about 326 adults with various advanced solid tumors who have already tried other therapies. Th…

This large study is testing whether the drug pembrolizumab can help prevent early-stage lung cancer from returning after surgery. It involves over 1,100 patients who have had their cancer surgically removed and completed standard chemotherapy. Participants receive either the acti…

This study is testing whether an injection treatment can help control advanced skin cancer that has returned or spread, or that cannot be removed by surgery. It involves 19 Japanese patients with this specific type of skin cancer. The main goal is to see if the treatment shrinks …

This study is testing whether adding one or two new drugs to the standard treatment works better for advanced kidney cancer. It involves about 249 Chinese patients who haven't had previous treatment for their advanced cancer. Researchers will compare how long patients live withou…

This early-stage trial is testing the safety and initial effectiveness of combining two targeted cancer drugs for people with advanced bladder cancer that has spread or cannot be removed by surgery. The study will involve about 38 participants who have already received standard c…

This study is testing whether adding new experimental drugs to a standard two-drug treatment works better for people with advanced bladder cancer that has spread. It will involve about 390 participants who have not yet received treatment for their advanced cancer. The main goals …

This study is testing whether an experimental drug called sacituzumab tirumotecan helps people with advanced stomach or esophageal cancer live longer than the current standard treatments. It is for people whose cancer has continued to grow despite trying at least two prior drug t…

This study aims to see if the body absorbs two cholesterol drugs, enlicitide and rosuvastatin, the same way when they are combined into one pill versus when taken as two separate pills. It involves 60 healthy adult participants. Researchers will measure drug levels in the blood a…

This early-stage study aims to check the safety and side effects of an experimental drug called MK-1167 in healthy adults. It will involve about 30 healthy volunteers and will closely monitor how their bodies react to the drug, including its effect on heart rhythm. The main goal …

This early-stage study is testing a new way to give the cancer drug pembrolizumab—as an injection under the skin instead of into a vein. The main goal is to see how much of the drug gets into the bloodstream and to check its safety when given this way. It involves 72 people with …

This study aims to understand how much of an experimental HIV prevention drug (MK-8527) passes into breast milk. Researchers will measure drug levels in the breast milk, blood, and plasma of 12 healthy, lactating women over 120 hours after they take a single dose. The goal is to …

This is a very early study to understand how two different pill versions of a potential Alzheimer's drug, called MK-1167, are processed by the body. It involves 16 healthy volunteers who will take the drug so researchers can measure its levels in the blood and check for safety. T…